Editorial Type: research-article
 | 
Online Publication Date: 03 Oct 2025

Practice Patterns Regarding Quality Assurance Measures in Gynecologic Cytology: Survey Results of Laboratories Participating in the 2022 College of American Pathologists PAP Education Program

MD,
MD,
MS,
SCT(ASCP),
MD,
MS, CT(ASCP)HT,
MD,
MD, PhD, and
MD
Article Category: Research Article
DOI: 10.5858/arpa.2025-0187-CP
Save
Download PDF

Context.—

Though numerous quality assurance (QA) measures are in place for the practice of gynecologic cytopathology, many of them are not clearly defined and may be variably used by laboratories worldwide.

Objective.—

To assess current practice patterns regarding the implementation of selected gynecologic cytology QA metrics to help develop guidance for laboratories.

Design.—

A supplemental questionnaire was mailed to laboratories participating in the 2022 College of American Pathologists (CAP) Gynecologic Cytopathology (PAP Education) Program requesting data regarding their QA measures in gynecologic cytology.

Results.—

A total of 562 laboratories responded to the supplemental questionnaire; responses from 511 laboratories were analyzed further. Of 492 laboratories, most considered Papanicolaou (Pap) tests from patients with untreated abnormal cytology in the previous year (386; 78.5%) or with an abnormal gynecologic biopsy finding (concurrent or within the past year) (331; 67.3%) as high-risk for negative rescreening. Many laboratories (436 of 511; 85.3%) required pathologist review of Pap tests for indications other than reactive/abnormal cells (eg, endometrial cells in women 45 years of age and older). For assessing cytologists’ performance, 88.5% (399 of 451) of respondents recorded the discrepancy rate between cytologist’s and pathologist’s interpretations. For monitoring pathologists’ performance, most laboratories (243 of 389; 62.5%) evaluated cases with significant cytologic-histologic discrepancy.

Conclusions.—

The CAP survey provided a detailed assessment of current QA practices regarding gynecologic cytology, which can aid laboratories in making decisions related to enhancement of QA in their setting. As the guidelines and tools for cervical cancer screening evolve, QA metrics will need to be accordingly refined.

Copyright: © 2025 College of American Pathologists 2025
pdf

Contributor Notes

Corresponding author: Abha Goyal, MD, Department of Pathology and Laboratory Medicine, Weill Cornell Medicine-New York Presbyterian Hospital, 525 E 68th St, F-766 C, New York, NY 10065 (email: abg9017@med.cornell.edu).

The authors have no relevant financial interest in the products or companies described in this article.

Supplemental digital content is available for this article. See text for hyperlink.

Souers is an employee of the College of American Pathologists.

Accepted: 29 Aug 2025
  • Download PDF